331 related articles for article (PubMed ID: 31787692)
1. Effect of Asfotase Alfa on Muscle Weakness in a Japanese Adult Patient of Hypophosphatasia with Low ALP Levels.
Koyama H; Yasuda S; Kakoi S; Ohata Y; Shimizu Y; Hasegawa C; Hayakawa A; Akiyama T; Yagi T; Aotani D; Imaeda K; Ozono K; Kataoka H; Tanaka T
Intern Med; 2020 Mar; 59(6):811-815. PubMed ID: 31787692
[TBL] [Abstract][Full Text] [Related]
2. Hypophosphatasia: From Diagnosis to Treatment.
Simon S; Resch H; Klaushofer K; Roschger P; Zwerina J; Kocijan R
Curr Rheumatol Rep; 2018 Sep; 20(11):69. PubMed ID: 30203264
[TBL] [Abstract][Full Text] [Related]
3. Asfotase alfa therapy for children with hypophosphatasia.
Whyte MP; Madson KL; Phillips D; Reeves AL; McAlister WH; Yakimoski A; Mack KE; Hamilton K; Kagan K; Fujita KP; Thompson DD; Moseley S; Odrljin T; Rockman-Greenberg C
JCI Insight; 2016 Jun; 1(9):e85971. PubMed ID: 27699270
[No Abstract] [Full Text] [Related]
4. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.
Scott LJ
Drugs; 2016 Feb; 76(2):255-62. PubMed ID: 26744272
[TBL] [Abstract][Full Text] [Related]
5. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Kishnani PS; Rockman-Greenberg C; Rauch F; Bhatti MT; Moseley S; Denker AE; Watsky E; Whyte MP
Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866
[TBL] [Abstract][Full Text] [Related]
6. Hypophosphatasia: Canadian update on diagnosis and management.
Khan AA; Josse R; Kannu P; Villeneuve J; Paul T; Van Uum S; Greenberg CR
Osteoporos Int; 2019 Sep; 30(9):1713-1722. PubMed ID: 30915507
[TBL] [Abstract][Full Text] [Related]
7. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.
Bowden SA; Adler BH
Osteoporos Int; 2018 Feb; 29(2):511-515. PubMed ID: 29046930
[TBL] [Abstract][Full Text] [Related]
8. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
Kishnani PS; Rush ET; Arundel P; Bishop N; Dahir K; Fraser W; Harmatz P; Linglart A; Munns CF; Nunes ME; Saal HM; Seefried L; Ozono K
Mol Genet Metab; 2017 Sep; 122(1-2):4-17. PubMed ID: 28888853
[TBL] [Abstract][Full Text] [Related]
9. Asfotase Alfa in Perinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia: A Guide to Its Use in the USA.
Scott LJ
BioDrugs; 2016 Feb; 30(1):41-8. PubMed ID: 26832358
[TBL] [Abstract][Full Text] [Related]
10. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia.
Rolvien T; Schmidt T; Schmidt FN; von Kroge S; Busse B; Amling M; Barvencik F
Bone; 2019 Oct; 127():67-74. PubMed ID: 31152801
[TBL] [Abstract][Full Text] [Related]
11. Enzyme Replacement Therapy in Hypophosphatasia.
Uçaktürk SA; Elmaogullari S; Ünal S; Gönülal D; Mengen E
J Coll Physicians Surg Pak; 2018 Sep; 28(9):S198-S200. PubMed ID: 30173697
[TBL] [Abstract][Full Text] [Related]
12. Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: Case report.
Freitas TQ; Franco AS; Pereira RMR
Medicine (Baltimore); 2018 Nov; 97(48):e13210. PubMed ID: 30508901
[TBL] [Abstract][Full Text] [Related]
13. Status Epilepticus due to Asfotase Alfa Interruption in Perinatal Severe Hypophosphatasia.
Ogawa E; Shimura K; Yoshihashi H; Miyama S
Pediatr Neurol; 2022 May; 130():4-6. PubMed ID: 35303588
[TBL] [Abstract][Full Text] [Related]
14. Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth.
Okazaki Y; Kitajima H; Mochizuki N; Kitaoka T; Michigami T; Ozono K
Eur J Pediatr; 2016 Mar; 175(3):433-7. PubMed ID: 26459154
[TBL] [Abstract][Full Text] [Related]
15. Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia.
Bowden SA; Adler BH
Osteoporos Int; 2018 Sep; 29(9):2155-2156. PubMed ID: 29967930
[No Abstract] [Full Text] [Related]
16. Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges.
Whyte MP
J Bone Miner Res; 2017 Apr; 32(4):667-675. PubMed ID: 28084648
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia.
Pan WJ; Pradhan R; Pelto R; Seefried L
J Clin Pharmacol; 2021 Oct; 61(10):1334-1343. PubMed ID: 33822385
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial.
Kitaoka T; Tajima T; Nagasaki K; Kikuchi T; Yamamoto K; Michigami T; Okada S; Fujiwara I; Kokaji M; Mochizuki H; Ogata T; Tatebayashi K; Watanabe A; Yatsuga S; Kubota T; Ozono K
Clin Endocrinol (Oxf); 2017 Jul; 87(1):10-19. PubMed ID: 28374482
[TBL] [Abstract][Full Text] [Related]
19. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa.
Kishnani PS; Del Angel G; Zhou S; Rush ET
Mol Genet Metab; 2021 May; 133(1):113-121. PubMed ID: 33814268
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Efficacy of Reduced Doses of Asfotase Alfa Replacement Therapy in an Infant With Hypophosphatasia Who Lacked Severe Clinical Symptoms.
Fujisawa Y; Kitaoka T; Ono H; Nakashima S; Ozono K; Ogata T
Front Endocrinol (Lausanne); 2020; 11():590455. PubMed ID: 33391183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
